Intelligent Document Processing (IDP) is reshaping the landscape of clinical trials within the healthcare sector, employing artificial intelligence (AI) and machine learning (ML) to streamline complex processes. In clinical trials generating over 13,000 documents in varied formats, IDP proves instrumental in automating data collection, organisation, and analysis. The result is a marked enhancement in productivity, accuracy, and significant cost savings for pharmaceutical companies.
Effective implementation of IDP in clinical trials requires meticulous assessment and planning, wherein organisations define goals, document processing needs, and address challenges such as data security and regulatory compliance. Selecting an appropriate IDP solution with robust AI/ML capabilities, seamless integration, and support for diverse document formats is critical. The implementation process involves key steps like quality auto-review, digital twinning, auto-translations, and sensitive data handling, ultimately leading to informed decision-making and improved trial efficiency.
Looking toward the future, a continued role for technology in pharmaceutical companies is expected, with an emphasis on the growing adoption of generative AI applications. As the industry leans further into digitisation, there is a forecast of developing and deploying "mini" versions of generative AI models. This strategic approach allows companies to harness the benefits of AI while safeguarding sensitive data quality and security, ultimately positioning themselves to capitalise on the full potential of AI in the pharmaceutical landscape.
Click here to read the original news story.